Delivery Order SPE2DB24D3013-SPE2DB25FFPRB
- Not listed
- The Defense Logistics Agency awarded a Delivery Order valued at $2,783.93 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count) on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The order represents a single transaction under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Rexulti 2 mg tablets in a quantity of 30 units, with a ceiling value of $3,299.21. This is a firm fixed price delivery order with no set-aside designation, reflecting a competitively awarded contract. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 28, 2025. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,566.78 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count packages) under a firm fixed-price contract type. This delivery order, issued on August 22, 2025, with an ultimate completion date of August 25, 2025, represents a non-competitive procurement executed without set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Rexulti 1 mg tablets in a 30-count package, with a contract ceiling value of $4,260.21. This non-set-aside, competitively awarded delivery order represents a firm fixed price transaction and is scheduled for completion by August 15, 2025. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Rexulti 2 mg tablets (quantity: 30 units) with a ceiling value of $2,927.61. This firm fixed-price delivery order, which was competitively awarded with no set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Rexulti 1 mg tablets (30-count) valued at $5,087.23 under a firm fixed-price contract. This award represents a non-competitive, non-set-aside delivery order executed through AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Rexulti 1 mg tablets (30-count units) with a ceiling value of $18,866.61. This non-set-aside contract award reflects a firm fixed price delivery order with an ultimate completion date of August 8, 2025. The contract is performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded a delivery order valued at $30,339.39 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count units) under a firm fixed price arrangement. The award, issued on July 29, 2025, with an ultimate completion date of July 30, 2025, represents a non-competitive delivery order placed against AmerisourceBergen's larger contract vehicle. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a $41,480.93 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Rexulti 1 mg tablets (30-count units). This firm fixed-price, competitively awarded contract with an ultimate completion date of July 29, 2025, represents a child order under AmerisourceBergen's larger pharmaceutical supply vehicle with the DLA. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order valued at $35,464.57 to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Rexulti 0.5 mg tablets in quantities of 30. This firm fixed price delivery order, with an ultimate completion date of July 25, 2025, represents a pharmaceutical supply transaction supporting federal medical procurement needs. The award was competitively awarded with no set-aside designation. Performance will be executed from AmerisourceBergen's corporate...
- SPE2DB24D3013Indefinite Delivery Contract
- SPE2DB24D3013-SPE2DB25FFPRBDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $17,977.69 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (quantity: 30 count) under a firm fixed price contract. The award was made on August 20, 2025, with an ultimate completion date of August 21, 2025. This is a non-set-aside competitive award, with performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract number SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle serves as a comprehensive global pharmaceutical support mechanism enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs and federal medical systems worldwide. AmerisourceBergen's federal contract portfolio demonstrates consistent capability in delivering diverse pharmaceutical commodities across multiple therapeutic domains to defense and civilian healthcare customers, including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $18.0k | 8/20/25 |